Provided by Tiger Fintech (Singapore) Pte. Ltd.

Context Therapeutics Inc.

0.7060
+0.05248.02%
Post-market: 0.70600.00000.00%17:46 EDT
Volume:129.91K
Turnover:88.51K
Market Cap:63.33M
PE:-0.98
High:0.7186
Open:0.6700
Low:0.6400
Close:0.6536
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
25 Feb

Sector Update: Health Care Stocks Rise Premarket Wednesday

MT Newswires Live
·
15 Jan

BRIEF-Context Therapeutics Says First Patient Dosed In The Phase 1 Clinical Trial Of CTIM-76

Reuters
·
15 Jan

Context Therapeutics Doses First Patient in Phase 1 Cancer Treatment Trial

MT Newswires Live
·
15 Jan

Context Therapeutics Advances CTIM-76 in Clinical Pipeline

TIPRANKS
·
15 Jan

Context doses first patient in Phase 1 clinical trial evaluating CTIM-76

TIPRANKS
·
15 Jan

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of Ctim-76

THOMSON REUTERS
·
15 Jan

BRIEF-Context Therapeutics Appoints Andy Pasternak As Chairman Of The Board Of Directors

Reuters
·
13 Jan

Context Therapeutics Names Andy Pasternak Board Chairman

MT Newswires Live
·
13 Jan

Context Therapeutics Inc - Richard Berman Steps Down From Context Board

THOMSON REUTERS
·
13 Jan

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

THOMSON REUTERS
·
13 Jan

Context Therapeutics Initiated at Market Outperform by JMP Securities

Dow Jones
·
08 Jan

Context Therapeutics Inc - Enters Sales Agreement With Leerink Partners

THOMSON REUTERS
·
03 Dec 2024

Context Therapeutics Inc - Under Sales Agreement, May Offer & Sell up to $75 Million in Common Stock

THOMSON REUTERS
·
03 Dec 2024

Context Therapeutics Initiated at Buy by D. Boral Capital

Dow Jones
·
25 Nov 2024